Table A3.
Additional Response Details
| Study | Year | Local Therapy | No. of Lesions | PR |
SD |
PD |
|||
|---|---|---|---|---|---|---|---|---|---|
| No. | Definition Used | No. | Definition Used | No. | Definition Used | ||||
| Heller et al* | 1996 | ECT | 10 | 2 | 50% reduction in tumor volume | 0 | NA | 5 | “No effect” |
| Heller et al* | 1996 | ECT | 2 | 0 | 50% reduction in tumor volume | 0 | NA | 0 | “No effect” |
| Sersa et al | 2000 | ECT† | 27 | 10 | > 50% reduction in tumor volume | 11 | < 25% increase or < 50% reduction in tumor volume | 3 | > 25% increase in tumor volume |
| Rodriguez-Cuevas et al* | 2001 | ECT | 13 | 8 | As listed | 0 | NA | 2 | “No response” |
| Rodriguez-Cuevas et al* | 2001 | ECT | 14 | 6 | As listed | 0 | NA | 0 | “No response” |
| Rodriguez-Cuevas et al* | 2001 | ECT | 2 | 2 | As listed | 0 | NA | 0 | “No response” |
| Byrne et al | 2005 | ECT | 53 | 5 | > 50% reduction in tumor area | 9 | Did not meet criteria for CR, PR, or PD | 5 | > 25% increase in lesion size |
| Gaudy et al | 2006 | ECT† | 24 | 3 | > 50% reduction in tumor area | 3 | Not meeting criteria for CR, PR, or PD | 1 | > 25% increase in tumor volume |
| Marty et al | 2006 | ECT | 171 | 19 | WHO 1997; > 50% reduction in diameter for ≥ 4 weeks | 18 | WHO 1997; ≤ 25% increase or < 50% reduction in tumor diameter | 8 | WHO 1997; > 25% increase in tumor diameter |
| Quaglino et al | 2008 | ECT | 233 | 80 | WHO 1997; > 50% reduction in tumor area for at least 4 weeks | 17 | WHO 1997; < 25% increase or < 50% reduction in tumor area | 0 | > 25% increase in tumor area |
| Matthiessen et al | 2011 | ECT | 94 | 18 | RECIST v1 2000; ≥ 30% decrease in target lesion | 11 | RECIST v1 2000; < 20% increase or < 30% decrease in target lesion | 7 | RECIST v1 2009; ≥ 20% increase in target lesion |
| Benevento et al | 2012 | ECT | 142 | 24 | RECIST v1 2000 | 11 | RECIST v1 2000; SD + NC | 0 | RECIST v1 2000 |
| Campana et al | 2012 | ECT | 35 | 13 | RECIST v1 2000 | 3 | RECIST v1 2000 | 0 | RECIST v1 2000 |
| Kendler et al* | 2013 | ECT | 50 | 0 | RECIST 2009; ≥ 30% decrease in tumor area | 23 | < 20% increase or < 30% decrease in tumor area | 22 | ≥ 20% increase in tumor area or an absolute increase of 5 mm |
| Kendler et al* | 2013 | ECT | 29 | 0 | RECIST 2009; ≥ 30% decrease in tumor area | 22 | < 20% increase or < 30% decrease in tumor area | 0 | ≥ 20% increase in tumor area or an absolute increase of 5 mm |
| Sperduto et al | 1991 | PDT | 20 | 9 | > 50% reduction in measurable nodules or a complete clinical regression with residual microscopic disease | 0 | NA | 7 | “No response: < 50% response, no change, or progression of disease” |
| Cairnduff et al | 1994 | PDT | 14 | 0 | 50% reduction in tumor size | 0 | NA | 9 | “No other responses were seen” |
| Baas et al | 1996 | PDT† | 20 | 3 | As listed | 0 | NA | 2 | “No change”‡ |
| Kaplan et al | 1998 | PDT | 13 | 0 | NA | 0 | NA | 0 | NA |
| Mang et al | 1998 | PDT | 86 | 7 | As listed | 0 | NA | 0 | NA |
| Overgaard et al | 1985 | RT | 15 | 5 | > 50% reduction in tumor area | 0 | < 25% progression or < 50% reduction in tumor area | 0 | > 25% progression of tumor area |
| Menendez et al | 2009 | RT | 88 | 9 | “Partial response” | 27 | “No change” | 0 | All lesions had either CR, PR, or SD‡ |
| Cohen et al | 1978 | ILT | 766 | NA | NA | NA | NA | 119 | Did not regress |
| Nathanson et al | 1979 | ILT | 22 | 7 | ≥ 50% decrease in diameters for minimum of 2 weeks | 1 | Listed as no change | 11 | ≥ 50% increase in diameters |
| Cascinelli et al | 1993 | ILT | 47 | NA | NA | NA | NA | 23 | Did not have an “objective response”‡ |
| Stewart et al* | 1999 | ILT | 8 | NA | NA | NA | NA | 6 | “No response” |
| Stewart et al* | 1999 | ILT | 15 | NA | NA | NA | NA | 10 | “No response” |
| Hoeller et al | 2001 | ILT | 29 | 2 | ≥ 50% reduction in size with no new lesions | 10 | < 25% increase in size or < 25% decrease in size | 9 | |
| Stopeck et al | 2001 | ILT | 7 | 3 | > 50% regression of tumor size‡ | 1 | ≤ 25% increase or ≤ 50% decrease in tumor size‡ | 1 | > 25% increase in tumor size‡ |
| Radny et al | 2003 | ILT | 244 | 16 | ≥ 50% tumor volume regression | NA | ≤ 25% increase or < 50% decrease in volume | NA | NA |
| Oratz et al | 2003 | ILT | 237 | 21 | > 50% decrease in sum of diameters | 0 | NA | 7 | “Progression” |
| Byrne et al | 2005 | ILT | 19 | 1 | > 50% reduction in tumor area | 3 | Did not meet criteria for CR, PR, or PD | 10 | > 25% increase in lesion size |
| Triozzi et al | 2005 | ILT | 14 | 0 | ≥ 50% reduction in volume | 2 | < 25% increase or < 25% decrease in volume | 12 | ≥ 25% increase in volume |
| Gonzalez et al | 2006 | ILT | 16 | 4 | > 50% reduction in tumor area | 3 | Not meeting criteria for CR, PR, or PD | 3 | > 25% increase in tumor volume |
| Kimata et al | 2006 | ILT | 77 | 5 | WHO; ≥ 50% reduction in area | 18 | WHO classification; < 25% increase or < 50% decrease in tumor area | 52 | WHO; > 25% increase in size or new lesions |
| Gaudy et al | 2006 | ILT† | 5 | 4 | Moderate to marked response: marked changes in one third or more of tumor cells | 1 | Mild response, mild changes in cancer cells or marked changes in less than one third of cancer cells | 0 | All had CR,PR, or SD‡ |
| Dummer et al | 2008 | ILT† | 25 | 2 | WHO; ≥ 50% reduction in size for ≥ 4 weeks | 3 | WHO; does not meet definition of CR, PR or PD | 16 | WHO; > 25% increase in size or new lesions |
| Hofmann et al | 2008 | ILT | 5 | 0 | NA | 1 | < 50% reduction in tumor area | 3 | > 20% increase in tumor area |
| Thompson et al | 2008 | ILT | 26 | 3 | RECIST JNCI 2000 | 7 | RECIST JNCI 2000 | 6 | NA |
| Bedikian et al | 2010 | ILT | 255 | 11 | RECIST JNCI 2000 | 32 | RECIST JNCI 2000 | 80 | NA |
| Weide et al | 2010 | ILT | 894 | 6 | ≥30% decrease in greatest single dimension | 146 | < 20% increase or < 30% decrease in greatest single dimension | 38 | ≥ 20% increase in greatest single dimension |
| Unger et al | 1992 | TT | 24 | 3 | “Partial remission” | 8 | “No change” | 9 | “Progressive disease” |
| Unger et al | 1993 | TT† | 52 | 10 | WHO criteria | 28 | WHO criteria | 13 | WHO criteria |
| Terwogt et al | 1999 | TT | 30 | 6 | ≥ 50% reduction in tumor size for ≥ 4 weeks | 10 | < 25% increase or < 50% decrease in tumor size | 7 | ≥ 25% increase in tumor size |
| Smorenburg et al | 2000 | TT† | 18 | 4 | WHO | 7 | 7 | WHO | |
| Leonard et al | 2001 | TT† | 19 | 6 | WHO 1979; ≥ 50% reduction in tumor area | 7 | < 25% increase or < 50% decrease in tumor area | 4 | ≥ 25% increase in tumor area |
| Eilender et al* | 2006 | TT† | 12 | 1 | ≥ 50% decrease in tumor area | 4 | < 25% increase or < 50% decrease in tumor area | 6 | ≥ 25 increase in tumor area |
| Eilender et al* | 2006 | TT | 5 | 2 | ≥ 50% decrease in tumor area | 0 | < 25% increase or < 50% decrease in tumor area | 3 | ≥ 25 increase in tumor area |
| Eilender et al* | 2006 | TT | 2 | 1 | ≥ 50% decrease in tumor area | 0 | < 25% increase or < 50% decrease in tumor area | 1 | ≥ 25 increase in tumor area |
| Eilender et al* | 2006 | TT | 4 | 2 | ≥ 50% decrease in tumor area | 0 | < 25% increase or < 50% decrease in tumor area | 2 | ≥ 25 increase in tumor area |
| Eilender et al* | 2006 | TT | 1 | 0 | ≥ 50% decrease in tumor area | 0 | < 25% increase or < 50% decrease in tumor area | 1 | ≥ 25 increase in tumor area |
| Salazar et al | 2011 | TT† | 10 | 4 | “Modified WHO criteria” | 2 | “Modified WHO criteria” | 1 | “Modified WHO criteria” |
| Florin et al | 2012 | TT | 45 | 25 | As listed: “partial response” | 1 | As listed: “stable disease” | 0 | As listed: “progressive disease” |
| Adams et al | 2012 | TT† | 10 | 2 | > 50% reduction in tumor area | 6 | < 25% increase or ≤ 50 reduction in tumor area‡ | 2 | ≥ 25% increase in tumor size |
| Plesnicar et al | 1982 | ILT + RT | 19 | 1 | “Incomplete reduction in volume of metastases” | 0 | NA | 4 | “Minimal or no response”‡ |
| Lai et al | 2003 | TT + RT | 7 | 3 | > 50% reduction in tumor area ≥ 4 weeks | 1 | < 25% increase or < 50% decrease in tumor area | 0 | ≥ 25% increase in tumor area or new lesions in treatment field |
| Green et al | 2007 | TT + ILT | 178 | 18 | ≥ 50% reduction in largest diameter | 53 | Did not meet criteria for CR, PR, or PD | 33 | Subcutaneous: ≥ 20% increase in largest diameter Cutaneous: any increase in size or pigmentation |
| Li et al | 2010 | TT + PDT | 11 | 3 | RECIST; ≥ 30% decrease in tumor area | 0 | < 20% increase or < 30% decrease in tumor area | 0 | ≥ 20% increase in tumor area or appearance of new lesions |
Abbreviations: CR, complete response; ECT, electrochemotherapy; ILT, intralesional therapy; JNCI, Journal of the National Cancer Institute; NA, not available; NC, no change; PD, progressive disease; PDT, photodynamic therapy; PR, partial response; RT, radiotherapy; SD, stable disease; TT, topical therapy.
*
Study split up by histology.
†
Systemic therapy allowed.
‡
Response definition was not clearly stated, and we implemented the listed definition of response.